International Journal of Clinical Research

Objective: To observe the clinical effect of compound probiotics in improving intestinal health. Methods A total of 100 patients with ulcerative colitis in our hospital from February 2020 to February 2021 were retrospectively selected, and they were divided into mesalazine single medication group (single medication group) and mesalazine combined with compound probiotics medication group ( Combined medication group) two groups, 50 cases in each group. Symptom scores, colonoscopy grades, serum TNF-α levels, intestinal mucosal barrier function, clinical efficacy, intestinal flora, and adverse reactions were statistically analyzed in the two groups. Results After treatment, the symptom score, colonoscopy grade, serum TNF-α level and L/M in the combined treatment group were lower than those in the single treatment group (P<0.05). The total effective rate of the patients in the combined drug group was 90.00% (45/50) higher than that in the single drug group (70.00% (35/50) (χ2=6.250, P<0.05). After treatment, the counts of Escherichia coli and Enterococcus faecalis in the combined treatment group were lower than those in the single treatment group (P<0.05), and the counts of Lactobacillus and Bifidobacterium were higher than those in the single treatment group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups at 16.00% (8/50) and 10.00% (5/50) (χ2=0.796, P>0.05). Conclusion The clinical effect of compound probiotics in improving intestinal health is good.

ulcerative colitis; mesalazine; compound probiotics; intestinal health; adverse reactions